Biohaven Ltd. (NYSE:BHVN - Get Rating) has earned an average recommendation of "Hold" from the ten brokerages that are currently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $95.17.
Several research analysts have recently weighed in on the company. Cowen set a $25.00 target price on Biohaven in a report on Monday, November 7th. Wedbush cut Biohaven from an "outperform" rating to a "neutral" rating and set a $148.50 target price on the stock. in a report on Monday, August 8th. Cowen lowered their target price on Biohaven to $25.00 in a report on Monday, November 7th. Piper Sandler lowered their target price on Biohaven from $23.00 to $21.00 and set an "overweight" rating on the stock in a report on Wednesday, October 26th. Finally, Cantor Fitzgerald upgraded Biohaven from a "neutral" rating to an "overweight" rating and lowered their target price for the stock from $158.00 to $27.00 in a report on Wednesday, October 26th.
Insider Activity at Biohaven
In other Biohaven news, Director Gregory Bailey acquired 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, October 25th. The shares were purchased at an average cost of $10.50 per share, for a total transaction of $2,100,000.00. Following the completion of the acquisition, the director now owns 1,507,971 shares of the company's stock, valued at approximately $15,833,695.50. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Gregory Bailey bought 200,000 shares of the business's stock in a transaction on Tuesday, October 25th. The shares were bought at an average price of $10.50 per share, with a total value of $2,100,000.00. Following the completion of the transaction, the director now directly owns 1,507,971 shares in the company, valued at $15,833,695.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vlad Coric bought 25,800 shares of the business's stock in a transaction on Monday, October 31st. The stock was purchased at an average cost of $15.97 per share, for a total transaction of $412,026.00. Following the transaction, the chief executive officer now owns 1,543,394 shares of the company's stock, valued at $24,648,002.18. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 1,263,967 shares of company stock worth $13,596,014. Insiders own 12.40% of the company's stock.
Institutional Trading of Biohaven
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. US Bancorp DE increased its position in shares of Biohaven by 19.1% during the first quarter. US Bancorp DE now owns 586 shares of the company's stock worth $70,000 after acquiring an additional 94 shares during the period. Victory Capital Management Inc. increased its position in shares of Biohaven by 6.4% during the first quarter. Victory Capital Management Inc. now owns 2,564 shares of the company's stock worth $229,000 after acquiring an additional 155 shares during the period. Washington Trust Advisors Inc. increased its position in shares of Biohaven by 24.6% during the first quarter. Washington Trust Advisors Inc. now owns 810 shares of the company's stock worth $96,000 after acquiring an additional 160 shares during the period. Palladiem LLC increased its position in shares of Biohaven by 10.5% during the second quarter. Palladiem LLC now owns 1,895 shares of the company's stock worth $276,000 after acquiring an additional 180 shares during the period. Finally, Level Four Advisory Services LLC increased its position in shares of Biohaven by 3.0% during the first quarter. Level Four Advisory Services LLC now owns 6,947 shares of the company's stock worth $824,000 after acquiring an additional 204 shares during the period. Hedge funds and other institutional investors own 78.19% of the company's stock.
Biohaven Trading Up 7.0 %
NYSE:BHVN opened at $15.34 on Wednesday. Biohaven has a 12 month low of $5.54 and a 12 month high of $17.39. The stock has a 50 day moving average of $52.29 and a two-hundred day moving average of $112.43. The firm has a market cap of $1.05 billion, a P/E ratio of -1.10 and a beta of 1.01.
Biohaven (NYSE:BHVN - Get Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($1.75) EPS for the quarter, topping the consensus estimate of ($2.53) by $0.78. On average, research analysts forecast that Biohaven will post -12.48 earnings per share for the current year.
Biohaven Company Profile
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an irreversible myeloperoxidase enzyme inhibitor for the treatment of neurodegenerative diseases.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to firstname.lastname@example.org.
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here